ArticleThe Laryngoscope2021
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.
Article in The Laryngoscope, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.JAMA otolaryngology-- head & neck surgery · 2022Trial
- Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP.The Laryngoscope · 2026Article
- Patient Perspectives on Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis.Laryngoscope investigative otolaryngology · 2026Article
- Comparison of COBioengineering (Basel, Switzerland) · 2026Article
- Development of a novel prognostic assessment tool for recurrent respiratory papillomatosis.BMC medicine · 2026Article
- DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRP.The Laryngoscope · 2025Observational
- Clinical Efficacy and Safety of Intralesional Bevacizumab in Dermatology: Insights from a Systematic Review.Dermatology practical & conceptual · 2025Review
- Chinese guideline for the diagnosis and treatment of juvenile-onset recurrent respiratory papillomatosis (2024).World journal of otorhinolaryngology - head and neck surgery · 2025Article
- Off-label drugs in laryngology- what should the doctor and the patient know about such therapies? A consensus statement of the European Laryngological Society.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Chinese guideline for the diagnosis and treatment of juvenile-onset recurrent respiratory papillomatosis (2024).Pediatric investigation · 2025Article
- Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis.The Laryngoscope · 2024Article
- Systemic bevacizumab for treatment of recurrent respiratory papillomatosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.The Annals of otology, rhinology, and laryngology · 2024Article
- Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2023Review
- Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single-center experience of eight patients.Laryngoscope investigative otolaryngology · 2023Article
- [Recurrent laryngeal papillomatosis].HNO · 2023Review
- Systemic Use of Bevacizumab for Recurrent Respiratory Papillomatosis: Who, What, Where, When, and Why?The Laryngoscope · 2023Article
- Use of cryotherapy to treat obstructing papilloma of an accessory tracheal bronchus: case report.Journal of cardiothoracic surgery · 2022Article
- Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis.Case reports in oncological medicine · 2022Article
- Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
75 authors at 20 institutions in 13 countries.
Funding
Abstract
objectives/hypothesisThe purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. STUDY
designDelphi method-based survey series.
methodsA multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up.
resultsThe international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).
conclusionThis consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. LEVEL OF EVIDENCE: 5 Laryngoscope, 131:E1941-E1949, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.